UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~November~~December, 2009.

Commission File Number 000-50656

InNexus Biotechnology Inc. (Translation of registrant’'s name into English)

1055 W. Hastings Street, Suite 2200 Vancouver, BC V6E 2E9
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F þ Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Note: Regulation S-T Rule 101(b)(7) only ~~permits~~ permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’'s “"home country”"), or under the rules of the home country exchange on which the registrant’'s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’'s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No þ

If “"Yes”" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________ .

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	InNexus Biotechnology Inc.
	(Registrant)
Date November 24, 2009	By	/s/ David Petulla
Date December 30, 2009	By	/s/ David Petulla
		(Signature)*
		David Petulla
		Chief Financial Officer

* Print the name and title under the signature of the signing officer.

EXHIBIT INDEX

EXHIBIT	DESCRIPTION OF EXHIBIT
99.1	~~Interim~~News ~~Financial~~Release ~~Statements~~dated ~~for~~December ~~the Period Ended September~~ 30, 2009
99.2	Management Discussion and Analysis for the Period Ended September 30, 2009
99.3	Form 52-109FV2 - Certification of Interim Filings - CEO
99.4	Form 52-109FV2 - Certification of Interim Filings - CFO

Filing Compare · InNexus Biotechnology Inc